Zetagen Therapeutics Announces First Patients Enrolled in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer
(400,000 patients annually are diagnosed with metastatic lytic bone lesions with only non-curative, palliative therapies available)
- ZetaMet™ (Zeta-BC-003) is a first-of-its kind molecular pathway designed to resolve metastatic cancer lesions, inhibit pain, and regenerate bone
- Phase 2a study examines the safety and efficacy of ZetaMet™ (Zeta-BC-003) for the treatment of metastatic bone lesions to the spine in Stage 4 breast cancer patients
- ZetaMet™ (Zeta-BC-003) has the potential to be a curative treatment, without systemic limitations, for metastatic lytic breast cancer lesions to bone
SYRACUSE, N.Y.–(BUSINESS WIRE)–Central New York Biotech Accelerator (CNYBAC) — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via local administration, for metastatic breast cancer to bone and soft tissues, announced today that the first two patients have enrolled in the phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions (ClinicalTrials.gov #NCT05280067).
